Published in J Neurochem on June 01, 1989
Plasma urate and risk of Parkinson's disease. Am J Epidemiol (2007) 3.06
Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A (1996) 2.88
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics (2009) 2.36
Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol (1999) 2.31
Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci U S A (1995) 2.01
Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem (2005) 1.95
The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci U S A (2004) 1.59
Delineation of an endogenous zinc-binding site in the human dopamine transporter. EMBO J (1998) 1.54
Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease. Clin Neurosci Res (2006) 1.50
Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. Mov Disord (2011) 1.44
Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. Neurobiol Dis (2012) 1.39
Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease. Free Radic Biol Med (2008) 1.38
The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br J Pharmacol (2005) 1.32
The role of NADPH oxidase 1-derived reactive oxygen species in paraquat-mediated dopaminergic cell death. Antioxid Redox Signal (2009) 1.31
Neurodegenerative diseases: an overview of environmental risk factors. Environ Health Perspect (2005) 1.30
Association of brefeldin A-inhibited guanine nucleotide-exchange protein 2 (BIG2) with recycling endosomes during transferrin uptake. Proc Natl Acad Sci U S A (2006) 1.25
Oxidative and nitrative protein modifications in Parkinson's disease. Free Radic Biol Med (2008) 1.25
Glutathione metabolism and Parkinson's disease. Free Radic Biol Med (2013) 1.20
Ageing and Parkinson's disease: why is advancing age the biggest risk factor? Ageing Res Rev (2014) 1.17
The Role of Oxidative Stress in Neurodegenerative Diseases. Exp Neurobiol (2015) 1.16
A delicate balance: Iron metabolism and diseases of the brain. Front Aging Neurosci (2013) 1.11
Integrated Laplacian-based phase unwrapping and background phase removal for quantitative susceptibility mapping. NMR Biomed (2013) 1.11
Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Mol Pathol (2001) 1.09
Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta (2008) 1.08
Iron prochelator BSIH protects retinal pigment epithelial cells against cell death induced by hydrogen peroxide. J Inorg Biochem (2008) 1.07
Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes. Biochim Biophys Acta (2013) 1.04
Different 8-hydroxyquinolines protect models of TDP-43 protein, α-synuclein, and polyglutamine proteotoxicity through distinct mechanisms. J Biol Chem (2011) 1.04
Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease. J Biol Chem (2009) 1.03
MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease. J Neurol (2005) 1.02
Structural and morphological characterization of aggregated species of α-synuclein induced by docosahexaenoic acid. J Biol Chem (2011) 1.02
Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration. Biomed Res Int (2014) 1.00
The modern management of Parkinson's disease. J Neurol Neurosurg Psychiatry (1990) 0.99
Detection of neuronal loss using T(1rho) MRI assessment of (1)H(2)O spin dynamics in the aphakia mouse. J Neurosci Methods (2008) 0.98
Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine. Br J Pharmacol (2002) 0.98
Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease. Prog Neurobiol (2015) 0.97
Lazaroids improve the survival of grafted rat embryonic dopamine neurons. Proc Natl Acad Sci U S A (1994) 0.95
Reactive oxygen species generation by the ethylene-bis-dithiocarbamate (EBDC) fungicide mancozeb and its contribution to neuronal toxicity in mesencephalic cells. Neurotoxicology (2007) 0.95
Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities. Antioxid Redox Signal (2013) 0.94
Glycoproteomics in neurodegenerative diseases. Mass Spectrom Rev (2009) 0.94
Combined elemental and biomolecular mass spectrometry imaging for probing the inventory of tissue at a micrometer scale. Anal Chem (2012) 0.93
Phosphorylation-dependent metal binding by alpha-synuclein peptide fragments. J Biol Inorg Chem (2006) 0.92
Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics (2014) 0.92
α-Synuclein and neuronal cell death. Mol Neurobiol (2012) 0.92
Mapping brain metals to evaluate therapies for neurodegenerative disease. CNS Neurosci Ther (2010) 0.91
Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J Neural Transm (Vienna) (1997) 0.90
The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease. Antioxid Redox Signal (2009) 0.90
Disrupted iron homeostasis causes dopaminergic neurodegeneration in mice. Proc Natl Acad Sci U S A (2016) 0.89
Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability. J Neural Transm (Vienna) (2006) 0.89
Impairment of interrelated iron- and copper homeostatic mechanisms in brain contributes to the pathogenesis of neurodegenerative disorders. Front Pharmacol (2012) 0.89
Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease. BMC Neurosci (2010) 0.88
Iron-dependent functions of mitochondria--relation to neurodegeneration. J Neural Transm (Vienna) (2010) 0.88
Combined Nurr1 and Foxa2 roles in the therapy of Parkinson's disease. EMBO Mol Med (2015) 0.88
A review of the use of magnetic resonance imaging in Parkinson's disease. Ther Adv Neurol Disord (2014) 0.88
L-DOPA treatment from the viewpoint of neuroprotection. Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson's disease. J Neurol (2005) 0.87
Dietary iron intake and risk of Parkinson's disease. Am J Epidemiol (2008) 0.87
Transcranial color-coded sonography helps differentiation between idiopathic Parkinson's disease and vascular parkinsonism. J Neurol (2007) 0.87
Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways. Neurobiol Dis (2014) 0.85
Dopamine D₂/D₃ agonists with potent iron chelation, antioxidant and neuroprotective properties: potential implication in symptomatic and neuroprotective treatment of Parkinson's disease. ChemMedChem (2011) 0.85
Parkinson's disease: oxidative stress and therapeutic approaches. Neurol Sci (2010) 0.85
Manganese efflux in Parkinsonism: insights from newly characterized SLC30A10 mutations. Biochem Biophys Res Commun (2013) 0.85
Quantitative susceptibility mapping of the midbrain in Parkinson's disease. Mov Disord (2015) 0.85
Subchronic polychlorinated biphenyl (Aroclor 1254) exposure produces oxidative damage and neuronal death of ventral midbrain dopaminergic systems. Toxicol Sci (2011) 0.85
Caenorhabditis elegans: a model to investigate oxidative stress and metal dyshomeostasis in Parkinson's disease. Front Aging Neurosci (2014) 0.84
Serum cholesterol and nigrostriatal R2* values in Parkinson's disease. PLoS One (2012) 0.83
Binding of alpha-synuclein with Fe(III) and with Fe(II) and biological implications of the resultant complexes. J Inorg Biochem (2009) 0.83
The history of the research of iron in parkinsonian substantia nigra. J Neural Transm (Vienna) (2012) 0.83
Mitochondrial dysfunction of immortalized human adipose tissue-derived mesenchymal stromal cells from patients with Parkinson's disease. Exp Neurobiol (2013) 0.82
Iron accumulation in Parkinson's disease. J Neural Transm (Vienna) (2012) 0.82
Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease. J Neural Transm (Vienna) (1997) 0.82
Mitochondrial metals as a potential therapeutic target in neurodegeneration. Br J Pharmacol (2014) 0.82
Targeting the progression of Parkinson's disease. Curr Neuropharmacol (2009) 0.82
Tracemetals, neuromelanin and neurodegeneration: An interesting area for research. Indian J Psychiatry (2007) 0.81
In vitro aggregation assays for the characterization of α-synuclein prion-like properties. Prion (2014) 0.81
Considerations for measuring iron in post-mortem tissue of Parkinson's disease patients. J Neural Transm (Vienna) (2012) 0.80
Transcriptional mutagenesis by 8-oxodG in α-synuclein aggregation and the pathogenesis of Parkinson's disease. Exp Mol Med (2015) 0.80
The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice. J Neural Transm (Vienna) (2006) 0.80
Copper and copper proteins in Parkinson's disease. Oxid Med Cell Longev (2014) 0.80
Modulation of DMT1 activity by redox compounds. J Membr Biol (2004) 0.80
Recent advances on the neuroprotective potential of antioxidants in experimental models of Parkinson's disease. Int J Mol Sci (2012) 0.80
Iron and Oxidative Stress in Parkinson's Disease: An Observational Study of Injury Biomarkers. PLoS One (2016) 0.79
Role of iron in neurodegenerative diseases. J Neural Transm (Vienna) (2016) 0.79
Neuronal response in Alzheimer's and Parkinson's disease: the effect of toxic proteins on intracellular pathways. BMC Neurosci (2015) 0.79
Alpha-synuclein aggregation is involved in the toxicity induced by ferric iron to SK-N-SH neuroblastoma cells. J Neural Transm (Vienna) (2010) 0.79
Meta-analysis of brain iron levels of Parkinson's disease patients determined by postmortem and MRI measurements. Sci Rep (2016) 0.79
Concerted action of metals and macromolecular crowding on the fibrillation of alpha-synuclein. Protein Pept Lett (2008) 0.78
Iron Accumulation Is Not Homogenous among Patients with Parkinson's Disease. Parkinsons Dis (2015) 0.78
Iron in neurodegenerative disorders of protein misfolding: a case of prion disorders and Parkinson's disease. Antioxid Redox Signal (2014) 0.78
Lateral Asymmetry and Spatial Difference of Iron Deposition in the Substantia Nigra of Patients with Parkinson Disease Measured with Quantitative Susceptibility Mapping. AJNR Am J Neuroradiol (2016) 0.78
Lack of increased oxidative stress in catechol-O-methyltransferase (COMT)-deficient mice. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.78
Association study of the G258S transferrin gene polymorphism and Parkinson's disease in the Spanish population. J Neurol (2005) 0.78
PKCδ mediates paraquat-induced Nox1 expression in dopaminergic neurons. Biochem Biophys Res Commun (2013) 0.77
Brain Iron Metabolism Dysfunction in Parkinson's Disease. Mol Neurobiol (2016) 0.77
The role of iron in neurodegenerative disorders: insights and opportunities with synchrotron light. Front Pharmacol (2014) 0.77
Activation of ATP-sensitive potassium channels enhances DMT1-mediated iron uptake in SK-N-SH cells in vitro. Sci Rep (2016) 0.77
The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease: A Mini Review. Oxid Med Cell Longev (2016) 0.77
Differences between conventional and nonconventional MRI techniques in Parkinson's disease. Funct Neurol (2013) 0.77
Carbonic anhydrase I, II, and VI, blood plasma, erythrocyte and saliva zinc and copper increase after repetitive transcranial magnetic stimulation. Am J Med Sci (2010) 0.76
Parkinson's Disease: The Mitochondria-Iron Link. Parkinsons Dis (2016) 0.76
Transcriptional regulation of the beta-synuclein 5'-promoter metal response element by metal transcription factor-1. PLoS One (2011) 0.76
Effect of chronic L-dopa or melatonin treatments after dopamine deafferentation in rats: dyskinesia, motor performance, and cytological analysis. ISRN Neurol (2012) 0.76
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry (1992) 33.67
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry (1988) 14.72
Corticocortical inhibition in human motor cortex. J Physiol (1993) 8.92
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology (1996) 8.82
Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain (1991) 8.16
Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med (1996) 6.57
A film of patients with movement disorders made in Queen Square, London in the Mid-1920s by Samuel Alexander Kinnier Wilson. Mov Disord (2011) 6.45
Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med (2013) 6.37
What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology (1992) 6.03
Mitochondrial complex I deficiency in Parkinson's disease. Lancet (1989) 5.72
Electric and magnetic stimulation of human motor cortex: surface EMG and single motor unit responses. J Physiol (1989) 5.69
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ (1999) 5.36
Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet (2004) 5.06
Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med (2000) 4.98
Servo action in the human thumb. J Physiol (1976) 4.93
Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med (1999) 4.79
Interhemispheric inhibition of the human motor cortex. J Physiol (1992) 4.77
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain (2005) 4.33
Servo action in human voluntary movement. Nature (1972) 4.33
The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain (1999) 4.25
Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem (1990) 4.03
Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry (2000) 3.89
Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol (1997) 3.80
Striatonigral degeneration. A clinicopathological study. Brain (1990) 3.70
Painful legs and moving toes. Brain (1971) 3.63
Validity and reliability of a rating scale for the primary torsion dystonias. Neurology (1985) 3.56
The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain (1994) 3.54
Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. J Neurol Neurosurg Psychiatry (1989) 3.53
Writers' cramp-a focal dystonia. Brain (1982) 3.43
Slater revisited: 6 year follow up study of patients with medically unexplained motor symptoms. BMJ (1998) 3.41
Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry (2002) 3.41
Outcome of investigation of patients with presenile dementia. Br Med J (1972) 3.39
Neuropathological features of Alzheimer's disease in non-demented parkinsonian patients. J Neurol Neurosurg Psychiatry (1991) 3.38
Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science (1990) 3.31
Stretch reflex and servo action in a variety of human muscles. J Physiol (1976) 3.29
Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet (1996) 3.26
Scope of a technique for electrical stimulation of human brain, spinal cord, and muscle. Lancet (1982) 3.26
The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture. Neurology (1982) 3.26
Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology (2001) 3.25
Corticobasal degeneration. Brain (1989) 3.20
Stimulation of the human motor cortex through the scalp. Exp Physiol (1991) 3.16
The impact of treatment with levodopa on Parkinson's disease. Q J Med (1980) 3.14
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology (2008) 3.10
Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology (2011) 3.10
A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol (1993) 3.00
Peripheral beta-adrenergic receptors concerned with tremor. Clin Sci (1967) 2.97
Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology (2006) 2.90
The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med (1980) 2.81
Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet (1988) 2.80
Motor cortex stimulation in intact man. 2. Multiple descending volleys. Brain (1987) 2.77
Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet (1997) 2.77
Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy. Ann Neurol (1995) 2.76
Classification of dystonia. Adv Neurol (1998) 2.75
Botulinum toxin in spasmodic torticollis. J Neurol Neurosurg Psychiatry (1988) 2.74
Blepharospasm-oromandibular dystonia syndrome (Brueghel's syndrome). A variant of adult-onset torsion dystonia? J Neurol Neurosurg Psychiatry (1976) 2.72
Cognitive deficits in the early stages of Parkinson's disease. Brain (1983) 2.65
Human walking and higher-level gait disorders, particularly in the elderly. Neurology (1993) 2.65
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol (1994) 2.65
Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain (1992) 2.64
Manual motor performance in a deafferented man. Brain (1982) 2.63
The anatomical basis of symptomatic hemidystonia. Brain (1985) 2.60
Neurosurgery in Parkinson disease: a distressed mind in a repaired body? Neurology (2006) 2.59
Is the human stretch reflex cortical rather than spinal? Lancet (1973) 2.58
Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet (2005) 2.56
"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet (1976) 2.54
Movement disorders in multiple sclerosis. Mov Disord (1995) 2.53
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain (1991) 2.52
The pathophysiology of primary dystonia. Brain (1998) 2.51
Pathophysiology of blepharospasm and oromandibular dystonia. Brain (1985) 2.50
A method of monitoring function in corticospinal pathways during scoliosis surgery with a note on motor conduction velocities. J Neurol Neurosurg Psychiatry (1986) 2.50
PINK1 protein in normal human brain and Parkinson's disease. Brain (2006) 2.49
Partially overlapping neural networks for real and imagined hand movements. Cereb Cortex (2000) 2.47
Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry (1988) 2.46
Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol (1990) 2.45
Changes in the response to magnetic and electrical stimulation of the motor cortex following muscle stretch in man. J Physiol (1991) 2.44
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry (1997) 2.42
Attitudes of families to some aspects of Huntington's chorea. Psychol Med (1979) 2.40
A study of hereditary essential tremor. Brain (1994) 2.37
Focal dystonia of the jaw and the differential diagnosis of unilateral jaw and masticatory spasm. J Neurol Neurosurg Psychiatry (1986) 2.37
'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain (1988) 2.36
The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. Neurology (1997) 2.36
Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology (1992) 2.36
Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat Genet (1995) 2.33
Disturbance of sequential movements in patients with Parkinson's disease. Brain (1987) 2.30
Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet (1990) 2.30
Abnormalities in central motor pathway conduction in multiple sclerosis. Lancet (1984) 2.30
Postural electromyographic responses in the arm and leg following galvanic vestibular stimulation in man. Exp Brain Res (1993) 2.30